Inventor · disambiguated record
Helene Margaret Finney
Also filed as: FINNEY HELENE M · FINNEY HELENE MARGARET
24 granted patents·10 pending applications·476 citations·filing 1996–2025
96Inventor score
Files withUCB BIOPHARMA SPRL16UCB Biopharma SRL7CELLTECH THERAPEUTICS LTD2UCB PHARMA SA2BROWN DEREK THOMAS1
Top patents by PatentIndex Score
34 records- 0198US7052906B1Synthetic transmembrane componentsCELLTECH R&D LTD·Filed 2000·Granted May 30, 2006·257 cites·10 claims
- 0297US10590197B2Antibody molecules which bind CD22UCB BIOPHARMA SPRL·Filed 2016·Granted Mar 17, 2020·14 cites·7 claims
- 0396US10358493B2Bispecific format suitable for use in high-through-put screeningUCB BIOPHARMA SPRL·Filed 2015·Granted Jul 23, 2019·14 cites·9 claims
- 0495US8926977B2Antibodies to the E1 extracellular loop of ion channelsMILLER KAREN MARGRETE·Filed 2010·Granted Jan 6, 2015·100 cites·9 claims
- 0593US10618957B2Antibody molecules which bind CD79UCB BIOPHARMA SPRL·Filed 2016·Granted Apr 14, 2020·9 cites·12 claims
- 0693US10370447B2Molecules with specificity for CD79 and CD22UCB BIOPHARMA SPRL·Filed 2015·Granted Aug 6, 2019·15 cites·11 claims
- 0791US11472879B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2020·Granted Oct 18, 2022·2 cites·20 claims
- 0890US10774152B2Molecules with specificity for CD45 and CD79UCB BIOPHARMA SPRL·Filed 2015·Granted Sep 15, 2020·5 cites·12 claims
- 0989US10954312B2Method employing bispecific protein complexUCB Biopharma SRL·Filed 2016·Granted Mar 23, 2021·5 cites·16 claims
- 1088US10233243B2Anti-FcRn antibodiesUCB BIOPHARMA SPRL·Filed 2013·Granted Mar 19, 2019·10 cites·17 claims
- 1188US9266953B2Methods of treating pain using function modifying NAv1.7 antibodiesUCB BIOPHARMA SPRL·Filed 2014·Granted Feb 23, 2016·8 cites·8 claims
- 1288US8734798B2Function modifying NAv 1.7 antibodiesFINNEY HELENE MARGARET·Filed 2010·Granted May 27, 2014·16 cites·23 claims
- 1387US11261252B2Molecules with specificity for CD79 and CD22UCB Biopharma SRL·Filed 2019·Granted Mar 1, 2022·2 cites·10 claims
- 1486US8986954B2DNA encoding function modifying Nav1.7 antibodiesUCB PHARMA SA·Filed 2014·Granted Mar 24, 2015·6 cites·6 claims
- 1583US2025346672A1Anti-fcrn antibodiesUCB Biopharma SRL·Filed 2025·Application pending·0 cites
- 1682US10273302B2Antibodies specific to FcRnUCB BIOPHARMA SPRL·Filed 2014·Granted Apr 30, 2019·5 cites·22 claims
- 1780US12338285B2Anti-FcRn antibodiesUCB Biopharma SRL·Filed 2022·Granted Jun 24, 2025·0 cites·52 claims
- 1880US11384148B2Anti-FcRn antibodiesUCB BIOPHARMA SPRL·Filed 2019·Granted Jul 12, 2022·1 cites·16 claims
- 1980US7052876B1Combinatorial method for producing nucleic acidsCELLTECH THERAPEUTICS LTD·Filed 2000·Granted May 30, 2006·6 cites·40 claims
- 2079US12331117B2Antibody molecules which bind CD22UCB Biopharma SRL·Filed 2022·Granted Jun 17, 2025·0 cites·20 claims
- 2171US2023287134A1Antibody molecules which bind cd45UCB Biopharma SRL·Filed 2023·Application pending·0 cites
- 2269US2022162311A1Antibodies specific to fcrnUCB BIOPHARMA SPRL·Filed 2021·Application pending·0 cites
- 2366US11220547B2Antibodies specific to FCRNUCB BIOPHARMA SPRL·Filed 2019·Granted Jan 11, 2022·0 cites·52 claims
- 2464US9738710B2Method of treating a patient for pain by administering an anti-ion channel antibodyUCB BIOPHARMA SPRL·Filed 2014·Granted Aug 22, 2017·0 cites·10 claims
- 2564US2019322739A1Bispecific format suitable for use in high-through-put screeningUCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 2661US9840556B2Anti-TNF alpha antibodies which selectively inhibit TNF alpha signalling through the p55RBROWN DEREK THOMAS·Filed 2005·Granted Dec 12, 2017·1 cites·10 claims
- 2758US11692041B2Antibody molecules which bind CD45UCB BIOPHARMA SPRL·Filed 2016·Granted Jul 4, 2023·0 cites·14 claims
- 2858US10112996B2Function modifying NAv1.7 antibodiesUCB BIOPHARMA SPRL·Filed 2016·Granted Oct 30, 2018·0 cites·12 claims
- 2953US2019359713A1Molecules with specificity for cd45 and cd79UCB BIOPHARMA SPRL·Filed 2019·Application pending·0 cites
- 3050US2003060444A1Cell activation process and reagents thereforCELLTECH THERAPEUTICS LTD·Filed 2002·Application pending·0 cites
- 3147US2009123944A1BioassaysUCB PHARMA SA·Filed 2006·Application pending·0 cites
- 3241US2006247191A1Chimeric cytoplasmic signalling moleculesFINNEY HELENE M·Filed 2003·Application pending·0 cites
- 3341US2004038886A1Chimeric cytoplasmic signalling molecules derived from cd137Filed 2001·Application pending·0 cites
- 3430US2003077249A1Cell activation process and reagents thereforFiled 1996·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Helene Margaret Finney files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →